BeiGene Ltd.

(BGNE) Trade

By |

Profile

BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

Contact Information

Website: www.beigene.com
Email: ir@beigene.com
Main Phone: +1 345 949-4123
Address: c/o Mourant Ozannes Corporate Services (Cayman) Limited
Address 2: 94 Solaris Avenue, Camana Bay
City / Town: Grand Cayman
Country: CYM
Postal Code: KY1-1108

Issuer Information

Exchange: NGS
CEO: John V. Oyler
Employees: 1700
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 133.85 $ 2.43 (1.85%)
Last Price 133.85 Change $ 2.43 Change % 1.85 Tick N/A
Bid 126.80 Bid Size 100.00 Ask 148.00 Ask Size 100.00
Open 130.63 High 134.87 Low 129.23 Prev Close 131.42
Last Trade Volume 437,945 52 Wk Hi 220.10 52 Wk Low 92.04
Market Cap 7.9 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 59,377,106.00 EPS (TTM) -9.75 PE Ratio N/A Exchange NGS
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 225 225 225 225
Low Target Price Estimate 197 197 172 200
Mean Target Price Estimate 207.25 207.25 201 211
Standard Deviation 12.55 12.55 22.02 10.55
Date of Most Recent Estimate 05/24/18 05/24/18 05/17/18 06/18/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 3
Moderate Buy 1 1 1 1
Hold 0 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.1 1.42 1.42 1.5